Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 4,159 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: STD Clear all
Completed Phase 2 Interventional

Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain

NCT00082316
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, HIV Infections, Peripheral Nervous System Diseases, Diabetic Neuropathies, Diabetes Mellitus, Polyneuropathies
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2008 · Synced Oct 19, 2026, 6:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Subclinical Atherosclerosis in HIV-infected Patients

NCT00455793
View directory record Official record
Conditions
HIV Infections, Coronary Atherosclerosis
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Not applicable Interventional

Effectiveness of Peer Navigation and Contingency Management on Retention in HIV Care

NCT02310893
View directory record Official record
Conditions
HIV/AIDS
Interventions
Combined Contingency Management and Peer Navigation, Contingency Management, Peer Navigation
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Sylmar, California • Van Nuys, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

NCT02462187
View directory record Official record
Conditions
Genital Warts, Perianal Warts
Interventions
NVN1000 8% Gel, NVN1000 16%, Vehicle, NVN1000 24%
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Fountain Valley, California • Lomita, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

B/F/TAF Ease of Swallowability Trial

NCT04600687
View directory record Official record
Conditions
HIV Infections
Interventions
Placebo tablets
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Not applicable Interventional

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals

NCT00001997
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-2, Polyethylene Glycolated, Zidovudine, Didanosine
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development of a Tailored HIV Prevention Intervention for Young Men

NCT02842060
View directory record Official record
Conditions
HIV Infections
Interventions
myDEx, NTHP
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 24 Years · Male only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks

NCT03293290
View directory record Official record
Conditions
HIV Infections
Interventions
PrEP
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Not applicable Interventional

SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir

NCT00002310
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Crofelemer
Drug
Lead sponsor
Shaman Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Francisco, California • Fort Lauderdale, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients

NCT00085917
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Double dose pegylated interferon with weight based Ribavirin, standard dose pegylated interferon alfa -2a and ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing a Dyadic Intervention for Sexually Transmitted Infection (STI)/HIV Prevention in Youth

NCT03275168
View directory record Official record
Conditions
Exposure to Sexually Transmissible Disorder (Event)
Interventions
Intervention, Individual evidence-based STI/HIV prevention intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
16 Years to 30 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Not applicable Interventional Results available

Building on Needle Exchange to Optimize Prevention & Treatment

NCT03567174
View directory record Official record
Conditions
Intravenous Drug Usage, HIV/AIDS
Interventions
Integrated care van (ICV)
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

NCT00001060
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 C4-V3 Polyvalent Peptide Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 19, 2026, 6:31 PM EDT
Completed No phase listed Observational

Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA)

NCT00312169
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Orlando Immunology Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Fresno, California • Los Angelos, California • Tarzana, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2008 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Phase 3 Interventional

A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX

NCT00002340
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Atovaquone, Pentamidine isethionate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Maitland, Florida • Tampa, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

NCT00735462
View directory record Official record
Conditions
Genital Warts
Interventions
2.5% imiquimod cream, 3.75% imiquimod cream, Placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Jonesboro, Arkansas • Carmichael, California • Chico, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Phase 3 Interventional

A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)

NCT00000727
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate, Pyrimethamine, Sulfamethoxazole/Trimethoprim, Sulfadoxine/Pyrimethamine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II, Open-Label Trial of Three Monoclonal Antibodies

NCT00219986
View directory record Official record
Conditions
HIV Infections
Interventions
Potent HAART during acute or early HIV-1 infection
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2007 · Synced Oct 19, 2026, 6:31 PM EDT
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

Characterization of Doxycycline Pharmacokinetics and Adherence

NCT07755618
View directory record Official record
Conditions
Sexually Transmitted Infection
Interventions
Single-Dose PK Phase - DR Group, Single-Dose PK Phase - IR Group, Multi-Dose PK Phase - Daily Group, Multi-Dose PK Phase - Intermittent Group
Drug
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 19, 2026, 6:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Atlas Genetics io® CTNG System

NCT03071510
View directory record Official record
Conditions
Chlamydia Trachomatis, Gonorrhea
Interventions
Atlas Genetics io® system
Device
Lead sponsor
Binx Health Limited
Industry
Eligibility
14 Years and older
Enrollment
7,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination

NCT03442062
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Assessment Feedback Incentives and eXchange, Physician-to-physician engagement, Active Intervention Control
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • Albany, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Phase 2 Interventional

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

NCT00000870
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Botswana TDF/FTC Oral HIV Prophylaxis Trial

NCT00448669
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg, Placebo Oral Tablet
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 39 Years
Enrollment
1,219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 19, 2026, 6:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Utilization of the Community Popular Opinion Leader (C-POL) Model in Alabama

NCT00260754
View directory record Official record
Conditions
Risk Behavior, Sexually Transmitted Diseases
Interventions
Community-Popular Opinion Leader Model, Diffusion of Innovations
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 31, 2006 · Synced Oct 19, 2026, 6:31 PM EDT